Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms

被引:0
|
作者
Chiara Saponaro
Melania Gaggini
Amalia Gastaldelli
机构
[1] Institute of Clinical Physiology,Cardiometabolic Risk Unit
[2] CNR,Dipartimento di Biotecnologie, Chimica e Farmacia
[3] Università di Siena,Dipartimento di Patologia Chirurgica, Molecolare Medica e di Area Critica
[4] Università di Pisa,undefined
来源
Current Diabetes Reports | 2015年 / 15卷
关键词
Fatty liver; Glucose intolerance; De novo lipogenesis; Lipotoxicity; Gut microbiota; Endocrine disruptors; NASH;
D O I
暂无
中图分类号
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is an independent risk factor for advanced liver disease, type 2 diabetes (T2DM), and cardiovascular diseases. The prevalence of NAFLD in the general population is around 30 %, but it is up to three times higher in those with T2DM. Among people with obesity and T2DM, the NAFLD epidemic also is worsening. Therefore, it is important to identify early metabolic alterations and to prevent these diseases and their progression. In this review, we analyze the pathophysiologic mechanisms leading to NAFLD, particularly, those common to T2DM, such as liver and muscle insulin resistance. However, it is mainly adipose tissue insulin resistance that results in increased hepatic de novo lipogenesis, inflammation, and lipotoxicity. Although genetics predispose to NAFLD, an unhealthy lifestyle, including high-fat/high-sugar diets and low physical activity, increases the risk. In addition, alterations in gut microbiota and environmental chemical agents, acting as endocrine disruptors, may play a role.
引用
收藏
相关论文
共 50 条
  • [21] Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus
    Fan, Yanbo
    Xiong, Wei
    Li, Jingjing
    Hu, Aimin
    He, Zhiwei
    Zhang, Jiawen
    Zhou, Guoyun
    Yin, Qiang
    PHARMACEUTICAL BIOLOGY, 2018, 56 (01) : 567 - 572
  • [22] Type 2 diabetes, congestive heart failure and nonalcoholic fatty liver disease
    Maechler, Maximilian
    Vonbank, Alexander
    Larcher, Barbara
    Mader, Arthur
    Sprenger, Lukas
    Leiherer, Andreas
    Zanolin-Purin, Daniela
    Muendlein, Axel
    Drexel, Heinz
    Saely, Christoph H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S354 - S354
  • [23] Dapagliflozin Therapy in Type 2 Diabetes Patients with nonalcoholic Fatty Liver Disease
    Kahl, S.
    DIABETOLOGE, 2018, 14 (07): : 506 - 508
  • [24] Type 2 diabetes, congestive heart failure and nonalcoholic fatty liver disease
    Maechler, M.
    Vonbank, A.
    Larcher, B.
    Mader, A.
    Sprenger, L.
    Leiherer, A.
    Zanolin-Purin, D.
    Muendlein, A.
    Drexel, H.
    Saely, C. H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S214 - S214
  • [25] The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus
    Xueyang Zhang
    Ran Bai
    Yong Jia
    Junwei Zong
    Yongbo Wang
    Yanan Dong
    International Journal of Diabetes in Developing Countries, 2020, 40 : 491 - 499
  • [26] Nonalcoholic Fatty Liver Disease The New Complication of Type 2 Diabetes Mellitus
    Bril, Fernando
    Cusi, Kenneth
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2016, 45 (04) : 765 - +
  • [27] Type 2 Diabetes, Congestive Heart Failure, and Nonalcoholic Fatty Liver Disease
    Maechler, Maximilian
    Vonbank, Alexander
    Larcher, Barbara
    Mader, Arthur
    Sprenger, Lukas
    Leiherer, Andreas
    Purin, Daniela
    Muendlein, Axel
    Drexel, Heinz
    Saely, Christoph H.
    DIABETES, 2020, 69
  • [28] Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease
    Newton, Kimberly P.
    Hou, Jiayi
    Crimmins, Nancy A.
    Lavine, Joel E.
    Barlow, Sarah E.
    Xanthakos, Stavra A.
    Africa, Jonathan
    Behling, Cynthia
    Donithan, Michele
    Clark, Jeanne M.
    Schwimmer, Jeffrey B.
    JAMA PEDIATRICS, 2016, 170 (10)
  • [29] Nonalcoholic fatty liver disease and the risk of type 2 diabetes in the United States
    Clark, JM
    Diehl, AM
    Brancati, FL
    DIABETES, 2001, 50 : A38 - A39
  • [30] Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: The Hidden Epidemic
    Ismail, Mona H.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2011, 341 (06): : 485 - 492